These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24726430)

  • 1. Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.
    Woulfe JM; Gray MT; Gray DA; Munoz DG; Middeldorp JM
    Parkinsonism Relat Disord; 2014 Jul; 20(7):685-94. PubMed ID: 24726430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinson's disease, a triggering role in the disease?
    Caggiu E; Paulus K; Arru G; Piredda R; Sechi GP; Sechi LA
    J Neuroimmunol; 2016 Feb; 291():110-4. PubMed ID: 26857504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?
    Halliday G; McCann H; Shepherd C
    Expert Rev Neurother; 2012 Jun; 12(6):673-86. PubMed ID: 22650170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sleep behavior disorder (RBD) in synucleionopaties].
    Glas Srp Akad Nauka Med; 2009; (50):7-15. PubMed ID: 20666111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging of alpha-synuclein in the olfactory bulb in a model of Parkinson's disease: cell types involved.
    Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Mohedano-Moriano A; Fradejas N; Calvo S; Argandoña-Palacios L; Garcia-Muñozguren S; Martinez-Marcos A
    Mov Disord; 2010 Aug; 25(11):1701-7. PubMed ID: 20574962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Parkinson's disease pathology be propagated from one neuron to another?
    Dunning CJ; Reyes JF; Steiner JA; Brundin P
    Prog Neurobiol; 2012 May; 97(2):205-19. PubMed ID: 22115849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus latent membrane protein 2A and autoimmunity.
    Swanson-Mungerson M; Longnecker R
    Trends Immunol; 2007 May; 28(5):213-8. PubMed ID: 17398159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut in Parkinson's disease: Bottom-up, top-down, or neither?
    Leclair-Visonneau L; Neunlist M; Derkinderen P; Lebouvier T
    Neurogastroenterol Motil; 2020 Jan; 32(1):e13777. PubMed ID: 31854093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis.
    Lin YS; Yeh TM; Lin CF; Wan SW; Chuang YC; Hsu TK; Liu HS; Liu CC; Anderson R; Lei HY
    Exp Biol Med (Maywood); 2011 May; 236(5):515-23. PubMed ID: 21502191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-CNS pathogenic origin of Parkinson's disease.
    Choudhry H; Perlmuter LC
    J Neurol; 2017 Sep; 264(9):2027-2030. PubMed ID: 28808780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
    Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
    Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.